Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 9128 results

  1. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development Reference number: GID-TA10685 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]

    Awaiting development Reference number: GID-TA11490 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    Awaiting development Reference number: GID-TA11813 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]

    Awaiting development Reference number: GID-TA11977 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]

    Awaiting development Reference number: GID-TA11981 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pain management (young people and adults)

    Awaiting development Reference number: GID-QS10093 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Heart valve disease in adults

    Awaiting development Reference number: GID-QS10101 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development